BBC0403 is a small-molecule selective inhibitor of Bromodomain-containing protein 2(BRD2) with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. It is a potential intra-articular injectable therapeutic agent for treating osteoarthritis (OA).

BBC0403 is a small-molecule selective inhibitor of Bromodomain-containing protein 2(BRD2) with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. It is a potential intra-articular injectable therapeutic agent for treating osteoarthritis (OA).

SDU-071 is an inhibitor of BRD4-p53 protein-protein interaction with IC50 of 2.7 μM, which suppresses MDA-MB-231 triple-negative breast cancer (TNBC) cell migration, invasion, and in vivo tumor growth. It also exhibits antiproliferative activity in concentration concentration-dependent manner, with IC50 of 10.5 μM (72 h) and 12.6 μM (96 h) in MDA-MB-231 cells.

BBC0403 is a small-molecule selective inhibitor of Bromodomain-containing protein 2(BRD2) with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. It is a potential intra-articular injectable therapeutic agent for treating osteoarthritis (OA).

SDU-071 is an inhibitor of BRD4-p53 protein-protein interaction with IC50 of 2.7 μM, which suppresses MDA-MB-231 triple-negative breast cancer (TNBC) cell migration, invasion, and in vivo tumor growth. It also exhibits antiproliferative activity in concentration concentration-dependent manner, with IC50 of 10.5 μM (72 h) and 12.6 μM (96 h) in MDA-MB-231 cells.

SDU-071 is an inhibitor of BRD4-p53 protein-protein interaction with IC50 of 2.7 μM, which suppresses MDA-MB-231 triple-negative breast cancer (TNBC) cell migration, invasion, and in vivo tumor growth. It also exhibits antiproliferative activity in concentration concentration-dependent manner, with IC50 of 10.5 μM (72 h) and 12.6 μM (96 h) in MDA-MB-231 cells.

SDU-071 is an inhibitor of BRD4-p53 protein-protein interaction with IC50 of 2.7 μM, which suppresses MDA-MB-231 triple-negative breast cancer (TNBC) cell migration, invasion, and in vivo tumor growth. It also exhibits antiproliferative activity in concentration concentration-dependent manner, with IC50 of 10.5 μM (72 h) and 12.6 μM (96 h) in MDA-MB-231 cells.

MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy.

KHK-6 is a potent ATP-competitive inhibitor of HPK1 kinase activity with an IC50 value of 20 nM. It significantly enhances CD3/CD28-induced production of cytokines by downregulating the HPK1-SLP-76 signaling cascade in the TCR signaling pathway.

KHK-6 is a potent ATP-competitive inhibitor of HPK1 kinase activity with an IC50 value of 20 nM. It significantly enhances CD3/CD28-induced production of cytokines by downregulating the HPK1-SLP-76 signaling cascade in the TCR signaling pathway.